Wall Street Zen Downgrades Organogenesis (NASDAQ:ORGO) to Hold

Organogenesis (NASDAQ:ORGO) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “hold” rating in a research report issued on Saturday.

Other research analysts have also issued research reports about the company. BTIG Research reduced their price target on Organogenesis from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Friday. Weiss Ratings restated a “sell (d+)” rating on shares of Organogenesis in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Organogenesis currently has an average rating of “Hold” and a consensus price target of $7.67.

Organogenesis Price Performance

ORGO stock opened at $3.21 on Friday. Organogenesis has a 1 year low of $2.61 and a 1 year high of $7.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. The firm has a market capitalization of $407.38 million, a PE ratio of 40.13 and a beta of 1.46. The business has a 50 day simple moving average of $4.23 and a 200-day simple moving average of $4.59.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.10. The firm had revenue of $225.61 million for the quarter, compared to the consensus estimate of $172.68 million. Organogenesis had a return on equity of 22.64% and a net margin of 5.32%. Equities research analysts anticipate that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Glenn H. Nussdorf sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the completion of the sale, the director directly owned 2,565,591 shares of the company’s stock, valued at approximately $13,187,137.74. This trade represents a 7.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 33.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Creative Planning increased its position in shares of Organogenesis by 8.2% during the third quarter. Creative Planning now owns 38,279 shares of the company’s stock valued at $162,000 after acquiring an additional 2,887 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Organogenesis by 52.8% during the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock worth $44,000 after purchasing an additional 2,953 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Organogenesis by 10.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 40,278 shares of the company’s stock valued at $209,000 after purchasing an additional 3,825 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Organogenesis by 57.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 14,522 shares of the company’s stock valued at $61,000 after purchasing an additional 5,273 shares during the last quarter. Finally, Quarry LP purchased a new stake in Organogenesis in the third quarter valued at approximately $25,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.

More Organogenesis News

Here are the key news stories impacting Organogenesis this week:

• Positive Sentiment: Record Q4 results — Organogenesis reported Q4 revenue of $225.6M (big beat) and EPS that topped estimates, with strong gross‑profit and operating‑profit expansion and materially higher operating cash flow. This explains recent upside in sentiment from the quarter’s beat. Organogenesis Reports Fourth Quarter 2025 Financial Results
• Neutral Sentiment: Analyst price‑target adjustment — BTIG trimmed its target from $9.00 to $8.00 but maintained a Buy rating, still implying substantial upside from today’s price. This keeps some analyst support but signals more cautious optimism. BTIG Price Target Update via Benzinga
• Negative Sentiment: Weak FY‑2026 guidance — management issued revenue guidance of $350M–$420M for FY‑2026, well below consensus (~$543M). The large gap between the outlook and street expectations is the primary driver of the stock weakening today. FY‑2026 Guidance and Earnings Release (MarketBeat)
• Negative Sentiment: Insider and institutional flows — notable insider selling (reported large insider sales) and mixed institutional activity (some large redemptions/position cuts) may add selling pressure or indicate some investors are booking gains after the strong quarter. QuiverQuant Coverage of Q4 Results & Insider Activity

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.